← Leaderboards
William Brian Dalton
Johns Hopkins University
$1,023,438
Attributed
$2,046,875
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $409.4K · FY2021–25$500K$375K$250K$125K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,046,875 · 2
By mechanism
R01$1,637,500 · 1
R56$409,375 · 1
Top collaborators
- Amy E Dezern5 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Jason Eli Farrar$2,896,875
- Kathleen C Barnes$47,663,132
- Robert A Brodsky$10,132,414
- Clara L Kielkopf$9,701,728
- Amy E Dezern$1,824,012
Others in their field
Other Emerging Leaders on “Disease Phenotype”
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Lynn Briscoe · Leidos Biomedical Research, Inc.$27,188,684
- Evan Z Macosko · Broad Institute, Inc.$27,107,011
- Badri N Vardarajan · University Of Miami School Of Medicine$25,174,816
Research focus
Disease PhenotypeDysmyelopoietic SyndromesDisease ModelAmino AcidsAnemiaBlood CellsBone MarrowAffectCell ModelCellsCellular BiologyBiologyClinical InvestigatorClinical PhenotypeClinical ResearchCollectionBiologicalCredentialingCytopeniaDaltonDifferentiation And GrowthDisease ClassificationDisease ManagementErythroid
Grant awards (5)
Biologic and Therapeutic Consequences of Distinct Hotspot SF3B1 Mutations in MDS$409,375
R01 · FY2025 · HL · contact PI
Biologic and Therapeutic Consequences of Distinct Hotspot SF3B1 Mutations in MDS$409,375
R01 · FY2024 · HL · contact PI
Biologic and Therapeutic Consequences of Distinct Hotspot SF3B1 Mutations in MDS$409,375
R01 · FY2023 · HL · contact PI
Biologic and Therapeutic Consequences of Distinct Hotspot SF3B1 Mutations in MDS$409,375
R01 · FY2022 · HL · contact PI
Biologic and Therapeutic Consequences of Distinct Hotspot SF3B1 Mutations in MDS$409,375
R56 · FY2021 · HL · contact PI